関連する実験動画
Updated: Jul 18, 2026
12:02
Assays for the Identification of Novel Antivirals against Bluetongue Virus
Published on: October 11, 2013
新型ABLキナーゼ阻害剤によるイマチニブ耐性が優勢である
Neil P Shah1, Chris Tran, Francis Y Lee
1Division of Hematology and Oncology, Department of Medicine, The David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA.
Science (New York, N.Y.)
|July 17, 2004
まとめ
新しい薬であるBMS-354825は,イマチニブ耐性を克服することによって,慢性骨髄性白血病 (CML) の治療に有望であることが示されています. この標的治療は,耐性BCR-ABL変異に対して有効であり,患者の改善への希望を提供します.
科学分野:
- 腫瘍学 腫瘍学
- 薬理学 薬理学とは
- 分子生物学は分子生物学である.
背景:
- 慢性骨髄性白血病 (CML) のイマチニブ耐性は,主にBCR-ABLキナーゼドメインの点変異によって引き起こされます.
- これらの変異は薬物結合を変化させ,CML患者の治療失敗につながります.
- 耐性メカニズムを理解することは,次世代の治療法の開発に不可欠です.
研究 の 目的:
- 新型ABLキナーゼ阻害剤であるBMS-354825のCMLにおけるイマチニブ耐性BCR-ABL変異に対する有効性を評価する.
- BCR-ABL誘発性白血病の臨床前モデルにおけるBMS-354825の治療の可能性を評価する.
主な方法:
- 抵抗性突然変異体への阻害剤結合を予測するために結晶学研究を利用した.
- 15のイマチニブ耐性BCR-ABL変異体に対するBMS-354825の活性を試験した.
- BCR-ABL誘発性疾患のマウスモデルと,患者の骨髄原始細胞でBMS-354825の有効性を評価した.
主要な成果:
- BMS-354825は,イマチニブ耐性BCR-ABL変異体15種のうち14種に対して継続的な活性を示した.
- 抑制剤は,BCR-ABL誘発性白血病のマウスで生存期間を大幅に延長しました.
- BMS-354825は,イマチニブに敏感な細胞と,イマチニブに抵抗性のある細胞の両方の増殖を抑制しました.
結論:
- BMS-354825は,イマチニブ耐性を与えるものを含む,広範なBCR-ABL変異のスペクトルに対して有効な強力な第2世代のABLキナーゼ阻害剤です.
- 耐性メカニズムに対する分子洞察は,優れた標的がん治療法の開発を効果的に導くことができます.
- BMS-354825は,イマチニブに耐性を発達したCML患者にとって重要な治療の可能性を示しています.
関連する概念動画
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...